ADAR and non-small cell lung carcinoma: In a clinical setting, patients with ADAR1 amplification, despite having NSCLC diagnosed in the early stages, have poor outcomes, signifying the downstream effects of ADAR1-associated activation on the RNA editing patterns and prognosis [129].